Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

Jun 10, 2040method-of-use (U-4030)US 12251365
Oct 21, 2035formulationUS 10174061
Oct 21, 2035compositionUS 10730895
Oct 21, 2035compositionUS 9446059

FDA exclusivities (1)

Oct 16, 2027NPNP1.2y

News(1)

AbbVie shares pressured as Q2 I&I beat falls below investor expectations
AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.
biospace · 11d ago

brand

Vyalev

generic

(foscarbidopa + foslevodopa)

MOA

12.1 Mechanism of Action VYALEV is a prodrug combination of foscarbidopa (carbidopa-4´-monophosphate) and foslevodopa (levodopa-4´-monophosphate). Foscarbidopa and foslevodopa are converted in vivo to carbidopa and levodopa. Carbidopa When levodopa is administered orally, it is rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system. Carbidopa inhibits the decarboxylation of peripheral levodopa, making more levodopa available for delivery to the brain. Levodopa Levodopa is the metabolic precursor of dopamine, does cross the blood-brain barrier, and presumably is converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa treats symptoms of Parkinson's disease.

indication

Parkinson's Disease

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 26m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

(foscarbidopa + foslevodopa)

Marketedupdated 3mo ago

by $ABBV AbbVie Inc.

Approved

community read0 votes

🐶 often sniffed alongside

top 2

Small molecule drug with a maximum clinical stage of Unknown, with 1 investigational indication.

indications

investigational

Parkinson's Disease

all catalysts(2)

approval · 2

VYALEV (FOSCARBIDOPA) — FDA approval

(foscarbidopa + foslevodopa)

VYALEV (FOSCARBIDOPA) — FDA approval

(foscarbidopa + foslevodopa)

→

Patent cliff

source: FDA Orange Book

first barrier falls

Oct 16, 2027

~1.2 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

Jun 10, 2040method-of-use (U-4030)US 12251365
Oct 21, 2035formulationUS 10174061
Oct 21, 2035compositionUS 10730895
Oct 21, 2035compositionUS 9446059

FDA exclusivities (1)

Oct 16, 2027NPNP1.2y

News(1)

AbbVie shares pressured as Q2 I&I beat falls below investor expectations
AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.
biospace · 11d ago

brand

Vyalev

generic

(foscarbidopa + foslevodopa)

MOA

indication

Parkinson's Disease

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 26m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

(foscarbidopa + foslevodopa)

🐶 often sniffed alongside

indications

all catalysts(2)

Patent cliff

patents (4)

FDA exclusivities (1)

News(1)

Report a data issue

comments(0)

(foscarbidopa + foslevodopa)

🐶 often sniffed alongside

indications

all catalysts(2)

Patent cliff

patents (4)

FDA exclusivities (1)

News(1)

Report a data issue

comments(0)